Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Edurant

    Client Email Product

    Edurant

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    13
    US DMFs Filed

    US DMFs Filed

    8
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    2
    Other Certificates

    Other Certificates

    3
    Other Suppliers

    Other Suppliers

    7
    API REF. PRICE (USD / KG)
    2,470

    API Market Place

    0

    INTERMEDIATES
    1
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    5
    Europe

    Europe

    1
    Canada

    Canada

    4
    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    213.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS
    235
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    25

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    15
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    left grey arrow
    right gray arrow
    • TABLET;ORAL - 200MG;EQ 25MG BASE;300MG
    • TABLET;ORAL - 200MG;EQ 25MG BASE;EQ 25MG BASE
    Full View ScreenFull Screen View
    NICE says yes to GSK's Cabenuva, new option for HIV patients
    NICE says yes to GSK's Cabenuva, new option for HIV patients

    https://www.fiercepharma.com/pharma/nice-gives-a-thumbs-up-to-gsk-s-cabenuva-giving-hiv-patients-attractive-treatment-option

    K. Dunleavy FIERCEPHARMA
    19 Nov 2021
    Share Share
    ViiV sees first global approval of Cabenuva in Canada
    ViiV sees first global approval of Cabenuva in Canada

    http://www.pharmatimes.com/news/viiv_sees_first_global_approval_of_cabenuva_in_canada_1329795

    Anna Smith PHARMATIMES
    23 Mar 2020
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Odefsey 208351 (Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate )Tablets
    FDA Confirms Paragraph IV Patent Challenge of Odefsey 208351 (Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate )Tablets

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-odefsey-208351-emtricitabine-rilpivirine-hydrochloride-and-tenofovir-alafenamide-fumarate-tablets-1578398200.pdf

    FDA
    07 Jan 2020
    Share Share
    FDA slams GSK's monthly HIV injectable with CRL, citing manufacturing issues
    FDA slams GSK's monthly HIV injectable with CRL, citing manufacturing issues

    https://endpts.com/fda-slams-gsks-monthly-hiv-injectable-with-crl-citing-manufacturing-issues/

    Amber Tong ENDPTS
    24 Dec 2019
    Share Share
    J&J-backed AIDS film picked up by Verizon Media
    J&J-backed AIDS film picked up by Verizon Media

    https://www.fiercepharma.com/marketing/j-j-sponsored-film-about-first-aids-ward-san-francisco-picked-up-for-broader-distribution

    Beth Snyder Bulik FIERCE PHARMA
    10 May 2019
    Share Share
    Prescription med: new or extended uses, new combinations of registered medicines
    Prescription med: new or extended uses, new combinations of registered medicines

    https://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines

    TGA
    09 Jul 2018
    Share Share
    Fresh off its Juluca approval, GSK beefs up trials of long-acting HIV duo
    Fresh off its Juluca approval, GSK beefs up trials of long-acting HIV duo

    https://www.fiercepharma.com/marketing/fresh-off-its-juluca-approval-glaxosmithkline-beefs-up-trials-long-acting-hiv-duo

    Carly Helfand FIERCE PHARMA
    28 Nov 2017
    Share Share
    ViiV’s long-acting two-drug HIV regimen hits targets
    ViiV’s long-acting two-drug HIV regimen hits targets

    http://www.pharmatimes.com/news/viivs_long-acting_two-drug_hiv_regimen_hits_targets_1199199

    Selina McKee PHARMA TIMES
    25 Jul 2017
    Share Share
    With two-drug combo data, GSK primes for an HIV market-share steal
    With two-drug combo data, GSK primes for an HIV market-share steal

    http://www.fiercepharma.com/pharma/gsk-s-hiv-combo-shines-pivotal-trial-as-gilead-mounts-a-challenge-to-blockbuster-tivicay

    Arlene Weintraub FIERCE PHARMA
    15 Feb 2017
    Share Share
    Gilead's latest HIV cocktail wins FDA approval with a blockbuster pedigree
    Gilead's latest HIV cocktail wins FDA approval with a blockbuster pedigree

    http://www.fiercebiotech.com/story/gileads-latest-hiv-cocktail-wins-fda-approval-blockbuster-pedigree/2016-03-01

    Damian Garde FIERCE BIOTECH
    01 Mar 2016
    Share Share
    J&J and ViiV line up Phase III trials for a long-acting HIV treatment
    J&J and ViiV line up Phase III trials for a long-acting HIV treatment

    http://www.fiercebiotech.com/story/jj-and-viiv-line-phase-iii-trials-long-acting-hiv-treatment/2016-02-24

    Damian Garde FIERCE BIOTECH
    25 Feb 2016
    Share Share
    ViiV to Progress Collaboration with Janssen to Develop First Long-acting
    ViiV to Progress Collaboration with Janssen to Develop First Long-acting

    http://www.prnewswire.com/news-releases/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv-1-infection-564500241.html

    PR NEWS WIRE
    08 Jan 2016
    Share Share
    ViiV Announces Positive Results from a Study for HIV Maintenance Therapy
    ViiV Announces Positive Results from a Study for HIV Maintenance Therapy

    http://www.prnewswire.com/news-releases/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy-539785671.html

    PR NEWS WIRE
    04 Nov 2015
    Share Share
    Gilead's low-dose, high-impact HIV drug heads to the FDA
    Gilead's low-dose, high-impact HIV drug heads to the FDA

    http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/04/gilead-gild-hiv-aids-taf-tenofovir.html

    Ron Leuty SAN FRANSISCO BUSINESS TIMES
    09 Apr 2015
    Share Share
    Gilead Announces Amended Agreements with Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment
    Gilead Announces Amended Agreements with Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment

    http://www.biospectrumasia.com/biospectrum/news/219943/gilead-janssen-extends-hiv-drug-partnership

    Press Release BIOSPECTRUM ASIA
    29 Dec 2014
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search